PMID- 28738051
OWN - NLM
STAT- MEDLINE
DCOM- 20180508
LR  - 20180508
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 21
IP  - 4 Suppl
DP  - 2017 Aug 1
TI  - BRAF/MEK 
Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma 
      Nursing Initiative on Managing Adverse Events and Potential Drug Interactions.
PG  - 11-29
LID - 10.1188/17.CJON.S4.11-29 [doi]
AB  - BACKGROUND: BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and 
      V600K-mutated unresectable or metastatic melanoma. However, these regimens are 
      associated with adverse events (AEs) that may lead to unnecessary drug 
      modifications and discontinuations or potentially serious sequelae. In addition, 
      drug-drug interactions (DDIs) may result in AEs or altered therapeutic 
      efficacy.
. OBJECTIVES: This article presents consensus statements to guide 
      nurses in the prevention, recognition, and management of AEs and potential DDIs 
      associated with BRAF/MEK inhibitor therapy. 
. METHODS: Members of the Melanoma 
      Nurse Initiative reviewed the current literature and clinical experience related 
      to AEs and DDIs associated with BRAF/MEK inhibitor therapy. 
. FINDINGS: The care 
      step pathways provided for select AEs represent a proactive, comprehensive 
      nursing care plan to support optimal patient outcomes. Recommendations are also 
      offered for preventing and managing DDIs.
FAU - Czupryn, Maria
AU  - Czupryn M
AD  - Moffitt Cancer Center.
FAU - Cisneros, Jennifer
AU  - Cisneros J
AD  - Moffitt Cancer Center.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Drug Interactions
MH  - Education, Nursing, Continuing
MH  - Humans
MH  - MAP Kinase Kinase Kinases/*antagonists & inhibitors
MH  - Melanoma/drug therapy/*nursing
MH  - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors
OTO - NOTNLM
OT  - BRAF
OT  - MEK
OT  - adverse events
OT  - drug-drug interactions
OT  - melanoma
OT  - targeted therapy
EDAT- 2017/07/25 06:00
MHDA- 2018/05/09 06:00
CRDT- 2017/07/25 06:00
PHST- 2017/07/25 06:00 [entrez]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2018/05/09 06:00 [medline]
AID - 10.1188/17.CJON.S4.11-29 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2017 Aug 1;21(4 Suppl):11-29. doi: 10.1188/17.CJON.S4.11-29.